Δευτέρα, 14 Δεκεμβρίου 2015

KADCYLA IMPROVES SURVIVAL AS SECOND LINE TREATMENT IN HER2+ BREAST CANCER

Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with ado-trastuzumab emtansine (aka T-DM1 [Kadcyla]) compared with those who received treatment of physician’s choice, according to results from the phase III TH3RESA clinical trial presented by Wildiers et al at the 2015 San Antonio Breast Cancer Symposium, held December 8–12 in San Antonio, Texas (Abstract S5-05).
Study Details
The HER2-targeted antibody-drug conjugate ado-trastuzumab emtansine was approved by the U.S. Food and Drug Administration in February 2013 for treating patients with HER2-positive, metastatic breast cancer that had progressed after treatment with trastuzumab and a taxane.
“The National Comprehensive Cancer Network guidelines, which are widely used as the standard for cancer care, were recently changed to recommend using [ado-trastuzumab emtansine] as a preferred treatment for patients with trastuzumab-exposed HER2-positive, metastatic breast cancer, meaning that it is generally used after a patient’s metastatic disease has progressed following treatment with a combination of a taxane-based chemotherapy and trastuzumab, with or without pertuzumab (Perjeta),” said Hans Wildiers, MD, PhD, Professor of Medical Oncology at KU Leuven in Belgium.
“However, there are a lot of patients who received second- or later-line treatment before this recommendation was put in place, and TH3RESA was designed to establish whether [ado-trastuzumab emtansine] could benefit patients in later lines as well,” he added.
“Previously published results from TH3RESA showed that [ado-trastuzumab emtansine] almost doubled progression-free survival,” continued Dr. Wildiers. “Here we show that [ado-trastuzumab emtansine] actually increased overall survival for heavily pretreated patients with HER2-positive, metastatic breast cancer. This is very important because several breast cancer therapies that increase progression-free survival do not in fact increase overall survival, and these patients urgently need new treatment options.”
All 602 patients with HER2-positive, metastatic breast cancer enrolled in TH3RESA had been previously treated with a chemotherapy regimen that included a taxane and, after a diagnosis of metastatic disease, two or more regimens that included HER2-targeted therapeutics, including trastuzumab and lapatinib. Patients were randomly assigned to 3.6 mg of ado-trastuzumab emtansine per kilogram of body weight every 3 weeks or treatment of physician’s choice.
Study Findings
After a median follow-up of 30.5 months, the median overall survival was significantly longer among the 404 patients assigned to ado-trastuzumab emtansine compared with the 198 patients assigned to treatment of physician’s choice: 22.7 months compared with 15.8 months. The overall survival benefit was seen regardless of patient age, hormone-receptor status, visceral involvement, and number of prior treatment regimens.
The incidence of grade 3 or higher adverse events was higher among patients assigned to treatment of physician’s choice compared with those assigned to ado-trastuzumab emtansine: 47.3% vs 40.0%.
“Not only did the population of patients assigned to [ado-trastuzumab emtansine] have increased median overall survival, they also had reduced incidence of grade 3 and higher adverse events,” said Dr. Wildiers. “The fact that these patients lived longer with less toxicity suggests that [ado-trastuzumab emtansine] is a good treatment option even for patients who have received two or more HER2-targeted treatment regimens.”
This study was supported by Roche. Dr. Wildiers’ institution has received compensation from Roche for lectures he has presented at national meetings and for consulting work, as well as an unrestricted research grant for academic research. 
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.

Δεν υπάρχουν σχόλια: